Cooper Companies Inc
NASDAQ:COO
Cooper Companies Inc
In the world of healthcare innovation, Cooper Companies Inc. etched its name as a significant player, specializing in creating products that enhance lives, particularly in the fields of vision care and women’s health. Established in 1958, Cooper Companies evolved to become a holding company operating through its two primary business units: CooperVision and CooperSurgical. CooperVision is renowned globally for its expertise in contact lenses, providing a diversified range of lenses to correct myopia, hyperopia, astigmatism, and presbyopia. By leveraging cutting-edge technology and a deep understanding of wearer needs, CooperVision caters to a wide spectrum of users, from daily disposables to specialty lenses, thus driving consistent revenue through the consumable nature of its products.
CooperSurgical, on the other hand, focuses on solutions for women’s health, offering a gamut of medical instruments, devices, and diagnostics. This unit extends Cooper Companies' footprint into the realms of fertility products, contraception, and obstetrics. By addressing key segments of the women’s health market, CooperSurgical supports clinical needs across a woman’s lifespan. Revenue opportunities here arise from both its durable medical equipment and consumable products, which ensure a stream of repeat business as healthcare providers replenish their supplies. Together, these divisions enable Cooper Companies to not only secure a robust market position but also continuously explore new areas for growth and expansion within the broader healthcare industry.
In the world of healthcare innovation, Cooper Companies Inc. etched its name as a significant player, specializing in creating products that enhance lives, particularly in the fields of vision care and women’s health. Established in 1958, Cooper Companies evolved to become a holding company operating through its two primary business units: CooperVision and CooperSurgical. CooperVision is renowned globally for its expertise in contact lenses, providing a diversified range of lenses to correct myopia, hyperopia, astigmatism, and presbyopia. By leveraging cutting-edge technology and a deep understanding of wearer needs, CooperVision caters to a wide spectrum of users, from daily disposables to specialty lenses, thus driving consistent revenue through the consumable nature of its products.
CooperSurgical, on the other hand, focuses on solutions for women’s health, offering a gamut of medical instruments, devices, and diagnostics. This unit extends Cooper Companies' footprint into the realms of fertility products, contraception, and obstetrics. By addressing key segments of the women’s health market, CooperSurgical supports clinical needs across a woman’s lifespan. Revenue opportunities here arise from both its durable medical equipment and consumable products, which ensure a stream of repeat business as healthcare providers replenish their supplies. Together, these divisions enable Cooper Companies to not only secure a robust market position but also continuously explore new areas for growth and expansion within the broader healthcare industry.
Revenue Record: Cooper Companies reported record Q4 revenue of $1.065 billion, up 4.6% year-over-year, with organic growth of 3.4%.
Earnings Beat: The company posted its eighth consecutive quarter of beating consensus earnings expectations, with non-GAAP EPS up 11% to $1.15.
Strong Free Cash Flow: Free cash flow hit $150 million in Q4, beating expectations, and full-year 2026–2028 free cash flow target was raised to over $2.2 billion.
Shareholder Returns: Nearly $200 million in stock repurchases were made in Q4, totaling almost $300 million for fiscal 2025; the repurchase authorization was increased to $2 billion.
Strategic Review: A formal strategic review was announced to explore options for maximizing shareholder value, with updates expected by the next earnings call.
MyDay & MiSight Momentum: MyDay daily silicone hydrogel lenses and MiSight for myopia control continue to drive growth, with MiSight sales up 37% and forecasted 20–25% growth for 2026.
Guidance Raised: Fiscal 2026 revenue is guided to $4.3–$4.34 billion (4.5%–5.5% organic growth), with free cash flow expected between $575 million and $625 million.
Cost Savings: Recent reorganization and integration efforts yielded significant cost savings, supporting margin expansion and improved cash generation.
